Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457858 | 0.92 | KCNJ1 (0.48) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL19457902 | 0.86 | HPGDS (0.42) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL19473769 | 0.85 | NSD2 (0.52) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL12445024 | 0.82 | KMT2A (0.54) | USP30ALDH1A1EPHX1MEN1KMT2A | |
| SCHEMBL20944523 | 0.82 | MEN1 (0.51) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL25151219 | 0.80 | ALDH1A1 (0.47) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL30398752 | 0.80 | ALDH1A1 (0.47) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL16984667 | 0.78 | USP30 (0.57) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL19457710 | 0.78 | USP30 (0.50) | USP30L3MBTL1ALDH1A1EPHX1MEN1 | |
| SCHEMBL19457848 | 0.77 | KCNJ1 (0.53) | USP30L3MBTL1EPHX1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231802-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3466945-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017211271-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | 江苏恒瑞医药股份有限公司 | 2017-12-14 | — | — | WO | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| EP-3231802-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2017-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | USP30 3131/4885L3MBTL1 4876/4885ALDH1A1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.